HK2 and hepatocellular carcinoma: The newly identified HK2‐ACSL4‐FAO axis is an ideal therapeutic target for HCC, and GalNac‐conjugated siRNA against HK2 opens an avenue to develop a novel strategy for precision therapy in the treatment of HCC.